Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Overview of attention for article published in The Breast, December 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 1,586)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered…

- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered…

Data to be discussed in a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium Preliminary Phase 2…

SAN DIEGO, December 09, 2022--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.